This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Myovant Sciences Future Growth

Future criteria checks 5/6

Key information

59.0%

Earnings growth rate

60.3%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate27.6%
Future return on equityn/a
Analyst coverage

Low

Last updated10 Mar 2023

Recent future growth updates

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Jan 26

Not The Buyout Offer That Myovant Shareholders Hoped For

Oct 25

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Oct 03

Women Can Thank Pfizer And Myovant For MYFEMBREE

Sep 20

Myovant Sciences: Regulatory Overhang Cleared

Aug 29

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Aug 09

Myovant stock gains ~6% after hours on Q1 revenue jump

Jul 27

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Jul 18

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Apr 28
Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Myovant: Poised To Overcome Regulatory Issues

Apr 26

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Apr 13

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Mar 26

Myovant: Catalysts Powering More Upside

Jan 02

Myovant Sciences: Becoming A Blockbuster

Jun 02

Myovant Sciences rises on FDA approval for relugolix

May 26

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

May 14
Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment

May 09

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Feb 17
New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Feb 13
Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Jan 12
Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Myovant cut to neutral at Goldman Sachs on ‘lack of driving catalysts’

Jan 06

Myovant Sciences announces distribution of ORGOVYX in the U.S.

Jan 05

Myovant Sciences gains 22% on relugolix deal with Pfizer

Dec 28

Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Dec 23
Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Myovant Sciences’ FDA win leads to Bullish views at Baird

Dec 21

Myovant Sciences scores FDA approval for Orgovyx in prostate cancer

Dec 18

Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Nov 18
Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Myovant Sciences: More Than Meets The Eye

Nov 12

The Sell-Off In Myovant Is Unjustified By Fundamentals

Nov 09

Earnings and Revenue Growth Forecasts

NYSE:MYOV - Analysts future estimates and past financials data ({{ reportingCurrencyISO }} {{ reportingUnit }})
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2025618-74N/AN/A2
3/31/2024555-76N/AN/A3
3/31/2023418-153N/AN/A2
12/31/2022379-184-271-270N/A
9/30/2022333-190-260-259N/A
6/30/2022306-166-232-231N/A
3/31/2022231-206-270-269N/A
12/31/2021198-228-263-261N/A
9/30/2021145-238403405N/A
6/30/202167-284318319N/A
3/31/202159-255369371N/A
12/31/202035-239443444N/A
9/30/202033-250-198-197N/A
6/30/202033-254-217-216N/A
3/31/2020N/A-289-222-221N/A
12/31/2019N/A-299-256-255N/A
9/30/2019N/A-284-252-250N/A
6/30/2019N/A-279-247-246N/A
3/31/2019N/A-274-225-224N/A
12/31/2018N/A-247-207-206N/A
9/30/2018N/A-218-176-175N/A
6/30/2018N/A-182-136-135N/A
3/31/2018N/A-143-118-117N/A
12/31/2017N/A-117-94-93N/A
9/30/2017N/A-83-70-69N/A
6/30/2017N/A-88-46-45N/A
3/31/2017N/A-83-19-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYOV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: MYOV is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MYOV is expected to become profitable in the next 3 years.

Revenue vs Market: MYOV's revenue (27.6% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: MYOV's revenue (27.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MYOV's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.